4.Recent Progress on Pharmaceutical Properties of Extracellular Vesicles from Mesenchymal Stem Cells--Review.
Yu-Shuang LIU ; Yuan SUN ; Zi-Kuan GUO
Journal of Experimental Hematology 2023;31(4):1247-1251
Mesenchymal stem cells (MSCs) have been officially approved in many countries to treat graft-versus-host disease, autoimmune disorders and those associated with tissue regeneration after hematopoietic stem cell transplantation. Studies in recent years have confirmed that MSC acts mainly through paracrine mechanism, in which extracellular vesicles secreted by MSC (MSC-EV) play a central role. MSC-EV has overwhelming advantages over MSC itself in the setting of adverse effects in clinical application, indicating that MSC-EV might take the place of its parent cells to be a potentially therapeutic tool for "cell-free therapy". The pharmaceutical properties of MSC-EV largely depend upon the practical and optimal techniques including large-scale expansion of MSC, the modification of MSC based on the indications and the in vivo dynamic features of MSC-EV, and the methods for preparing and harvesting large amounts of MSC-EV. The recent progresses on the issues above will be briefly reviewed.
Humans
;
Extracellular Vesicles
;
Hematopoietic Stem Cell Transplantation/adverse effects*
;
Mesenchymal Stem Cell Transplantation/methods*
;
Mesenchymal Stem Cells
;
Pharmaceutical Preparations
5.Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis.
Shunquan WU ; Zongjian QIU ; Ting LIN ; Zhijuan ZHU ; Xiaofan LI ; Xianling CHEN ; Ping CHEN ; Yiting WANG ; Rong ZHAN ; Nainong LI
Chinese Medical Journal 2023;136(15):1873-1875
10.Expression and Prognostic Impact of HK2 in Bone Marrow of Patients with Newly Diagnosed Acute Myeloid Leukemia.
Ping MA ; Li-Huan SHI ; Liang TIAN ; Ya-Feng WANG ; Jian-Wen ZHOU ; Yan-Na MAO ; Wei LIU ; Yu-Wei HOU ; Hui SUN
Journal of Experimental Hematology 2023;31(5):1309-1314
OBJECTIVE:
To detect the expression level of HK2 gene in the bone marrow of newly diagnosed patients with acute myeloid leukemia (AML) and investigate its influence on the clinical characteristics and prognosis.
METHODS:
The expression level of HK2 gene in the bone marrow of 90 newly diagnosed patients with AML that accompanying clinical characteristics and survival status were detected by RT-qPCR, and compared with 18 allogeneic hematopoietic stem cell transplantation (allo-HSCT) donors. The Chi-square test, Kaplan-Meier survival analysis, and Cox proportional hazards regression model were used to analyze the correlation of HK2 expression level with clinical characteristics and prognosis.
RESULTS:
Compared with allo-HSCT donors, the HK2 expression was significantly increased in newly diagnosed AML patients (P <0.01). Compared with patients with total response (OR, complete response + complete response with incomplete hematologic recovery) after 2 courses of induction chemotherapy, the expression of HK2 in patients without OR was significantly increased (P <0.05). There was a significant difference in the relative expression of HK2 between patients with and without OR after 2 courses of induction therapy (P <0.001). The median survival time of patients with high expression of HK2 was significantly shorter than that of patients with low expression of HK2 (P <0.05). The multivariate Cox proportional hazards regression analysis showed that prognostic stratification, the expression level of HK2, and whether two courses of induction therapy achieved OR were independent factors affecting the prognosis of AML patients (P <0.05).
CONCLUSIONS
Compared with allo-HSCT donors, the expression level of HK2 gene is increased in the bone marrow of newly diagnosed AML patients. The prognosis of patients with high expression of HK2 is poor. The expression level of HK2 is an independent factor affecting the prognosis of AML patients.
Humans
;
Bone Marrow
;
Hematopoietic Stem Cell Transplantation/adverse effects*
;
Leukemia, Myeloid, Acute/therapy*
;
Prognosis
;
Retrospective Studies
;
Transplantation, Homologous/adverse effects*